Orion Corporation, a Finnish pharmaceutical and diagnostics company, has received favorable pharmacokinetic study results with combined salmeterol-fluticasone formulation of the Easyhaler® product ...

Orion Corporation has received Irish and Hungarian marketing authorisation for Bufomix Easyhaler®, an inhaled budesonide-formoterol combination product indicated for asthma and chronic obstructive ...

Nycomed / Nycomed and Orion Corporation to collaborate on Easyhaler® for asthma and COPD . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this ...

Propeller Health is partnering up with Orion to bring its digital inhaler platform to the Finnish drugmaker’s Easyhaler line of products. The 2015 Fierce 15 company will help develop a small, custom ...

(ShareCast News) - Hikma Pharmaceuticals has signed an exclusive licensing and distribution agreement with Finland's Orion for its new Easyhaler combination product for the treatment of asthma and ...

Propeller Health’s digital respiratory health platform will be making a bigger splash among European patients thanks to a partnership announced yesterday with Finnish pharmaceuticals and diagnostics ...

In response to the increasing demand for its products, Orion will invest a total of approximately EUR 30 million in the coming years to increase its production capacity in Finland. The investments ...

ORION CORPORATION STOCK EXCHANGE RELEASE 14 APRIL 2014 at 9:30 PM EEST Orion receives first marketing authorisations for Bufomix Easyhaler® product Orion Corporation has received Irish and Hungarian ...